| | GAITHERSBURG, Md., April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023. At WVC, Novavax will present data on its COVID-19 prototype vaccine as a booster and its CIC. Novavax will also host an Insights and Tools to Counter Vaccine Hesitancy roundtable on April 4, and participate in a panel discussion on The Future of Safety for New Vaccines on April 5. In addition, Novavax has been named a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards (ViE) in the Best New Vaccine Technology/Platform Award and Best COVID Vaccine Award categories. Winners will be announced in-person at the ViE Awards ceremony during WVC on April 4. At ECCMID, the Company will present the CIC data and four poster presentations on its COVID-19 prototype vaccine. Novavax presentations during WVC: | Author | Presentation title | Details | | Dunkle, L | Novavax COVID-19 Vaccine:
Latest Booster Data and Clinical
Updates | Oral Presentation April 5, 2023 10:10am (EDT) | | Shinde, V | Update on Novavax Influenza
and COVID-
Influenza Combination Vaccine | Oral Presentation April 5, 2023 3:25pm (EDT) | | Fix, J | Safety surveillance for COVID-19
vaccines: challenges in the
pandemic and endemic settings | Oral Presentation April 5, 2023 12:10pm (EDT) | Novavax presentations during ECCMID: | Author | Presentation title | Details | | Shinde, V | Immunogenicity of a novel
COVID-Influenza Combination
(CIC) vaccine assessed with
response surface modelling
(RSM) | Oral Presentation Abstract #02042 April 16, 2023 8:30am (CEST) | | Toback, S | Interim analysis of an observer-
blinded, randomized phase 3
study to evaluate the safety and
immunogenicity of a single
booster of the NVX-CoV2373
vaccine in adults previously
vaccinated with the BBIBP-CorV
vaccine | Poster Presentation Poster #P2698 April 17, 2023 12:00pm (CEST) | | Marchese, A | Reported pregnancy outcomes
across NVX-CoV2373 COVID-19
vaccine primary series and
booster dose clinical studies | Poster Presentation Poster #P2521 April 17, 2023 12:00pm (CEST) | | Marchese, A | Healthcare provider perceptions of
current and future uptake of
COVID-19 vaccines in Europe and
North America | Poster Presentation Poster #P2755 April 17, 2023 12:00pm (CEST) | | Bennett, C | LATE-BREAKER: Immunogenicity
of a SARS-CoV-2 recombinant
spike protein nanoparticle vaccine
with Matrix-M adjuvant (NVX-
CoV2373) in well-controlled vs
less well-controlled people living
with HIV | Poster Presentation Poster #LB039 April 18, 2023 12:00pm (CEST) | About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. Focused on the world’s most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information. The World Vaccine Congress
The World Vaccine Congress is a series of conferences and exhibitions that have grown over 23 years to become the largest vaccine meetings of their kind across the globe. The event format allows for whole-sector topics with hundreds of speakers and covers the complete vaccine value chain, enabling thousands of attendees from science, government, and manufacturers to come together to create ground-breaking progress. More information can be found at https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm. CONTACTS Investors
Erika Schultz
240-268-2022
ir@novavax.com Media
Ali Chartan
240-720-7804
media@novavax.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-grows-presence-at-world-vaccine-congress-2023-and-33rd-european-congress-of-clinical-microbiology--infectious-diseases-301788683.html
SOURCE Novavax, Inc. | |
